2018
DOI: 10.1186/s13195-018-0448-x
|View full text |Cite
|
Sign up to set email alerts
|

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

Abstract: BackgroundThe quantification of amyloid-beta (Aβ) peptides in blood plasma as potential biomarkers of Alzheimer’s disease (AD) is hampered by very low Aβ concentrations and the presence of matrix components that may interfere with the measurements.MethodsWe developed a two-step immunoassay for the simultaneous measurement of the relative levels of Aβ38, Aβ40 and Aβ42 in human EDTA plasma. The assay was employed for the study of 23 patients with dementia of the Alzheimer’s type (AD-D) and 17 patients with demen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

8
49
0
4

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 50 publications
(61 citation statements)
references
References 32 publications
8
49
0
4
Order By: Relevance
“…We observed significantly lower levels of plasma Aβ T42:T40 in patients with AD than in CN older adults, as has been previously reported [2–18]. In addition, a trend for lower plasma Aβ F42:F40 in patients with AD was also observed.…”
Section: Discussionsupporting
confidence: 89%
See 2 more Smart Citations
“…We observed significantly lower levels of plasma Aβ T42:T40 in patients with AD than in CN older adults, as has been previously reported [2–18]. In addition, a trend for lower plasma Aβ F42:F40 in patients with AD was also observed.…”
Section: Discussionsupporting
confidence: 89%
“…Specifically, previous studies have suggested that plasma levels of Ab, tau, and other target proteins, such as neurofilament light, amyloid precursor protein, and others, are altered in patients with AD and those in the prodromal stage of AD, mild cognitive impairment (MCI). A number of studies have suggested that plasma Ab42 and Ab40 measures, as well as the ratio of Ab42/ Ab40 are reduced in patients with AD and MCI and that these plasma biomarkers can predict the presence of AD and MCI and progression from normal to impaired cognition [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. However, other studies have shown that higher plasma Ab measures are associated with AD and conversion to AD [19][20][21][22][23][24].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Commercial sandwich ELISA Plasma Aβ42 in AD patients increases (58), decreases (59,61), or is irrelevant (57,62) [57][58][59]61,62 Two-step immunoassay Plasma Aβ42/Aβ40 ratios correlate with AD diagnosis 90,91 Oral Aβ42…”
Section: Aβ42mentioning
confidence: 99%
“…Zeitlich parallel entwickelte die Arbeitsgruppe von Jens Wiltfang in Göttingen einen 2-schrittigen Immuno-Essay zur Messung von Aß1-42 und Aß1-40 im Blut, was Hochdurchsatzmessungen ermöglicht [4]. Die Arbeitsgruppe verglich Patienten mit über Liquor-Biomarker bzw.…”
Section: Blutbasierte Messungen Des ß-Amyloidunclassified